These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 20959364

  • 1. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
    Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA.
    J Pharmacol Exp Ther; 2011 Jan; 336(1):242-53. PubMed ID: 20959364
    [Abstract] [Full Text] [Related]

  • 2. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
    Pieschl RL, Miller R, Jones KM, Post-Munson DJ, Chen P, Newberry K, Benitex Y, Molski T, Morgan D, McDonald IM, Macor JE, Olson RE, Asaka Y, Digavalli S, Easton A, Herrington J, Westphal RS, Lodge NJ, Zaczek R, Bristow LJ, Li YW.
    Eur J Pharmacol; 2017 Jul 15; 807():1-11. PubMed ID: 28438647
    [Abstract] [Full Text] [Related]

  • 3. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
    Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.
    J Pharmacol Exp Ther; 2007 May 15; 321(2):716-25. PubMed ID: 17308038
    [Abstract] [Full Text] [Related]

  • 4. Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.
    Callahan PM, Terry AV, Tehim A.
    Psychopharmacology (Berl); 2014 Sep 15; 231(18):3695-706. PubMed ID: 24595504
    [Abstract] [Full Text] [Related]

  • 5. LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization.
    Verma MK, Goel RN, Bokare AM, Dandekar MP, Koul S, Desai S, Tota S, Singh N, Nigade PB, Patil VB, Modi D, Mehta M, Gundu J, Walunj SS, Karche NP, Sinha N, Kamboj RK, Palle VP.
    Eur J Pharmacol; 2021 Jan 15; 891():173685. PubMed ID: 33127363
    [Abstract] [Full Text] [Related]

  • 6. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
    Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE.
    J Pharmacol Exp Ther; 2005 Mar 15; 312(3):1213-22. PubMed ID: 15523001
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
    Boess FG, de Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, König G.
    Psychopharmacology (Berl); 2013 May 15; 227(1):1-17. PubMed ID: 23241647
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.
    Neuropsychopharmacology; 2007 Jan 15; 32(1):17-34. PubMed ID: 16936709
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D.
    Neuropharmacology; 2009 Jan 15; 56(1):254-63. PubMed ID: 18793655
    [Abstract] [Full Text] [Related]

  • 16. Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B.
    Tang JS, Xie BX, Bian XL, Xue Y, Wei NN, Zhou JH, Hao YC, Li G, Zhang LR, Wang KW.
    Acta Pharmacol Sin; 2015 Jul 15; 36(7):800-12. PubMed ID: 25948478
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).
    Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M.
    J Med Chem; 2012 May 24; 55(10):4806-23. PubMed ID: 22468936
    [Abstract] [Full Text] [Related]

  • 19. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
    Bristow LJ, Easton AE, Li YW, Sivarao DV, Lidge R, Jones KM, Post-Munson D, Daly C, Lodge NJ, Gallagher L, Molski T, Pieschl R, Chen P, Hendricson A, Westphal R, Cook J, Iwuagwu C, Morgan D, Benitex Y, King D, Macor JE, Zaczek R, Olson R.
    PLoS One; 2016 May 24; 11(7):e0159996. PubMed ID: 27467081
    [Abstract] [Full Text] [Related]

  • 20. Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.
    Cilia J, Cluderay JE, Robbins MJ, Reavill C, Southam E, Kew JN, Jones DN.
    Psychopharmacology (Berl); 2005 Oct 24; 182(2):214-9. PubMed ID: 16001118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.